Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Locarnini

Showing results (121-130 of 132) with videos related to

Pageof 14
Sort By:
Gastroenterology|June 10, 2004
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapyBettina Werle-Lapostolle, Scott Bowden, Stephen Locarnini, et al.
The Journal of Infectious Diseases|May 18, 2005
Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype CHenry L Y Chan, Stephen K W Tsui, Chi-Hang Tse, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 15, 2013
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virusGail V Matthews, Eric C Seaberg, Anchalee Avihingsanon, et al.
Journal of Viral Hepatitis|May 9, 2020
HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis BLilly Yuen, Peter A Revill, Gillian Rosenberg, et al.
Journal of Virology|January 25, 2008
Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virusJoseph J Y Sung, Stephen K W Tsui, Chi-Hang Tse, et al.
Hepatology (Baltimore, Md.)|June 24, 2008
Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistanceScott Preiss, Margaret Littlejohn, Peter Angus, et al.
Scientific Reports|November 25, 2015
Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine TherapyBin Zhou, Hui Dong, Yungang He, et al.
Gut|August 19, 2016
Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis BJulianne Bayliss, Lilly Yuen, Gillian Rosenberg, et al.
Journal of Virology|May 22, 2009
Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfectionJ Judy Chang, Sunee Sirivichayakul, Anchalee Avihingsanon, et al.
Hepatology International|July 24, 2015
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 updateYun-Fan Liaw, Jia-Horng Kao, Teerha Piratvisuth, et al.
Pageof 14

Showing results (121-130 of 132) with videos related to

Sort By:
Pageof 14
Gastroenterology|June 10, 2004
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapyBettina Werle-Lapostolle, Scott Bowden, Stephen Locarnini, et al.
The Journal of Infectious Diseases|May 18, 2005
Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype CHenry L Y Chan, Stephen K W Tsui, Chi-Hang Tse, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 15, 2013
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virusGail V Matthews, Eric C Seaberg, Anchalee Avihingsanon, et al.
Journal of Viral Hepatitis|May 9, 2020
HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis BLilly Yuen, Peter A Revill, Gillian Rosenberg, et al.
Journal of Virology|January 25, 2008
Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virusJoseph J Y Sung, Stephen K W Tsui, Chi-Hang Tse, et al.
Hepatology (Baltimore, Md.)|June 24, 2008
Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistanceScott Preiss, Margaret Littlejohn, Peter Angus, et al.
Scientific Reports|November 25, 2015
Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine TherapyBin Zhou, Hui Dong, Yungang He, et al.
Gut|August 19, 2016
Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis BJulianne Bayliss, Lilly Yuen, Gillian Rosenberg, et al.
Journal of Virology|May 22, 2009
Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfectionJ Judy Chang, Sunee Sirivichayakul, Anchalee Avihingsanon, et al.
Hepatology International|July 24, 2015
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 updateYun-Fan Liaw, Jia-Horng Kao, Teerha Piratvisuth, et al.
Pageof 14